Michael Higgins

Michael Higgins currently serves as Chief Executive Officer and Executive Chairman of Kindex Pharmaceuticals. An experienced biotechnology executive, Mr. Higgins has held leadership roles in finance, operations, and business development with both large multi-national organizations and small entrepreneurial firms. Previously, he served as Chief Operating Officer and Chief Financial Officer (CFO) at Ironwood Pharmaceuticals from 2003 through 2014. In 2014, Mr. Higgins was named Boston Business Journal’s CFO of the Year. Mr. Higgins worked at Genzyme Corporation from 1997 through 2003 in a variety of leadership roles, including Vice President of Corporate Finance and Vice President of Business Development. While at Genzyme, he was involved with multiple business units, including cell therapy, gene therapy, and orphan diseases. Mr. Higgins also served as Chief Financial Officer at Procept, Inc. from 1992 to 1997. He began his pharmaceutical career as a sales representative for Schering-Plough Corporation.

Mr. Higgins currently serves as Chairman of Voyager Therapeutics’ Board of Directors. He also serves on the boards of several additional public and privately held companies, including Genocea Biosciences, Inc., Pulmatrix, Inc., CAMP4, Sea Pharmaceuticals, and Private Equity Access Fund, II.

Mr. Higgins holds a Bachelor of Science degree from Cornell University and a Master of Business Administration from the Amos Tuck School of Business at Dartmouth College.